Hamada S, et al. - In non-squamous non-small cell lung cancer (NSCLC) patients receiving chemotherapy, researchers investigated whether bevacizumab (Bev, a monoclonal antibody against vascular endothelial growth factor [VEGF]) could attenuate acute exacerbation of interstitial lung disease (AE-ILD) risk. This study included 48 patients with advanced non-squamous NSCLC with ILD. The incidence of AE-ILD and outcomes were analyzed in patients who were treated with first-line chemotherapy with (Bev group, n = 17) and without (non-Bev group, n = 31) Bev. For both groups, they performed Gray’s test. According to the findings, in patients with lung cancer, the risk of chemotherapy-related AE-ILD may be attenuated by adding Bev to chemotherapy regimens.